A few pilot studies have already demonstrated that anti‐HER2‐targeted therapy was able to successfully eliminate HER2‐positive single circulating and disseminated tumour cells in non‐metastatic and metastatic BC.38, 39, 40. Here, ERBB2 is linked to neoplasm.